News

These high-risk patients typically do not respond well to standard therapies. These results were published in The Lancet Oncology. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and

One hundred and sixteen patients in 46 clinical centers from 12 countries participated in the study. Final protocol pre-specified Independent Data Monitoring Committee (IDMC) review on the first

The two parties have also entered into an exclusive license agreement that allows BMS to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration. Bristol-Myers Squibb

Benzac treats stubborn acne and prevents new breakouts from forming with salicylic acid, while pharmaceutical-grade East Indian Sandalwood Oil calms and soothes the skin. In a clinical study,

Mr. Shailesh Shah, President and CEO, today states that SOHM received a boost in its restructuring process when the buyer confirmed committed orders for minimum $ 300,000 and

The aerosol foam formulation of the fixed combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, has been developed to improve treatment for patients with plaque psoriasis. The NDA is

The injection is designed to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS). Previously, gadavist was approved for

The company also secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to

The transaction also includes intellectual property and a technology platform related to a second, undisclosed vaccine program. CMV is a herpes virus and one out of every five